Supplement users and sleep
According to CRN's Consumer Survey on Dietary Supplements, 70% of supplement users regularly get a good night's sleep compared with 62% of non-users.
For sleep health, the top choices among supplement users, according to CRN’s survey are:
Chamomile / lavender (tied at 3%)
Lemon balm / valerian (tied at 2%)
Melatonin also ranked high for mental health support. Of those users who reported taking supplements for mental health, 5% used melatonin for this reason, second only to vitamin B/B complex at 8%. CBD also made the list, tied with magnesium at 4%.
CRN Recommended Guidelines for Labeling and Formulation of Melatonin-containing Dietary Supplements for Sleep Support
Regulatory resources for mental health, sleep claims
Mental health and sleep supplement products can benefit consumers as they seek wellness support during these challenging times.
By the numbers: Passing the $1 billion mark, mood and mental health supplement sales grew by 29.4% in 2020 and sleep supplements by 36.6%, with continued growth expected, according to data from Nutrition Business Journal.
Yes, but: Marketers must be mindful of FDA and FTC regulations when making claims. In February, FDA issued 10 warning letters to companies selling dietary supplements claiming to treat or prevent depression and other mental health disorders.
“When developing marketing plans and products, it’s not only about what will sell or what consumers are interested in, we have to ensure we have the regulatory and legal sides taken care of and so substantiation, clinical trials and ensuring you have appropriate structure-function claims is crucial,” advises CRN Senior Vice President and Associate General Counsel Megan Olsen.
Regulatory resources to help marketers steer clear of disease claims include:
Small Entity Compliance Guide on Structure/Function Claims
Structure Function Claims Notifications to FDA—notifications of product claims to FDA in 2021 are accessible within docket FDA-2021-S-0024; and letters of objections are accessible within the docket FDA-1997-S-0006